Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Latour Capital and Sulo on the acquisition of San Sac Group
Mandate

Vinge advises Latour Capital and Sulo on the acquisition of San Sac Group

January 10, 2020 M&A

Sulo is a leading international manufacturer of bins, underground and semi-underground systems for collection and separation of recyclable materials.

Based in Linköping, Sweden, San Sac Group has built a worldwide network in over 40 countries with about 500 employees and three plants in Sweden and France and a turnover of EUR 170m.

Vinges’s team consisted of responsible partner Matthias Pannier and senior associate Manne Bergström, together with Stina Bengtsson, Milad Kamali, Emelie Svanberg (M&A), Sofia Törnroth Nyberg, Axel Jansson (Banking and Finance), Maria Schultzberg, Henrik Wastenson, Victor Ericsson (Tax), Lisa Hörnqvist (Commercial Agreements) and Jessica Öijer (Project Assistance).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026